Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Neurocrine Biosciences (NBIX) - Neurocrine Biosciences currently holds a Momentum Style Score of B, indicating a favorable momentum outlook [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Performance Metrics - Over the past week, NBIX shares increased by 2.53%, while the Zacks Medical - Drugs industry remained flat [6] - In the last month, NBIX's price change was 1.97%, outperforming the industry's 1.66% [6] - Over the past quarter, NBIX shares rose by 12.04%, and over the last year, they increased by 24.37%, compared to the S&P 500's gains of 6.22% and 17.55%, respectively [7] Trading Volume - The average 20-day trading volume for NBIX is 815,114 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, three earnings estimates for NBIX have been revised upward, while none have been revised downward, increasing the consensus estimate from $4.41 to $4.49 [10] - For the next fiscal year, two estimates have moved up, while one has been revised down [10] Conclusion - Considering the positive momentum indicators and earnings outlook, NBIX is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Core Viewpoint - Growth investors seek stocks with above-average financial growth, but identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - Neurocrine Biosciences (NBIX) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 12.9%, with projected EPS growth of 36.4% this year, significantly surpassing the industry average of 19% [5] Group 2: Financial Metrics - Cash flow growth for Neurocrine is currently at 35.4%, well above the industry average of 3.2% [6] - The annualized cash flow growth rate over the past 3-5 years is 39.5%, compared to the industry average of 6.9% [7] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Neurocrine, with the Zacks Consensus Estimate for the current year increasing by 1.7% over the past month [8] - Neurocrine holds a Zacks Rank of 2 (Buy) and a Growth Score of B, indicating its potential as a solid choice for growth investors [10]

Core Insights - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has experienced a strong six-month performance with double-digit gains, recovering from 52-week lows recorded in April 2025, although the past month has seen marginal losses of less than one percent [1] Company Performance - The stock of Neurocrine Biosciences, Inc. has shown significant recovery over the last six months, indicating positive market sentiment and potential growth opportunities [1] Analyst Background - Gamu Dave Innocent Pasi is a seasoned financial professional with extensive experience in financial analysis and investment research, contributing to reputable publications and focusing on actionable trading ideas and investment recommendations [1] Investment Philosophy - Gamu emphasizes the importance of Responsible Investment and actively promotes Environmental, Social, and Governance (ESG) principles in investment decision-making, reflecting a growing trend in the investment community towards sustainability and social impact [1] Future Focus - The company is currently focused on building a new international investment portfolio, indicating a strategic move towards global market engagement and diversification [1]

Core Insights - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has experienced a strong six-month performance with double-digit gains, recovering from 52-week lows recorded in April 2025, although the past month has seen marginal losses of less than one percent [1] Company Performance - The stock of Neurocrine Biosciences, Inc. has shown significant recovery over the last six months, indicating positive market sentiment and potential investor confidence [1] Analyst Background - Gamu Dave Innocent Pasi is a seasoned financial professional with extensive experience in financial analysis and investment research, contributing to reputable publications and focusing on actionable trading ideas and investment recommendations [1] Investment Philosophy - Gamu emphasizes the importance of Responsible Investment and actively promotes Environmental, Social, and Governance (ESG) principles in investment decision-making, reflecting a growing trend in the investment community towards sustainability and social impact [1] Future Focus - The company is currently focused on building a new international investment portfolio, indicating a strategic move towards global market engagement and diversification [1]

Core Insights - Neurocrine Biosciences presented a post-hoc analysis from the Phase 3 KINECT 4 study, showing that continuous treatment with INGREZZA (valbenazine) at a 40 mg dose for 48 weeks led to significant improvements in tardive dyskinesia (TD) symptoms [1][5][6] Study Findings - The KINECT 4 study demonstrated that 90% of participants who completed 48 weeks of treatment with INGREZZA 40 mg achieved a 50% improvement in the Abnormal Involuntary Movement Scale (AIMS) total score [5][6] - Efficacy was assessed through clinician- and patient-reported measures, with sustained improvements observed throughout the treatment period [4][6] - The analysis included 45 patients on the 40 mg dose and 11 patients who escalated to 80 mg before reducing back to 40 mg, showing similar therapeutic benefits [3][6] Safety and Tolerability - The safety profile of INGREZZA remained consistent with previous studies, with most treatment-emergent adverse events being mild to moderate [4][9] - Common side effects included sleepiness and tiredness, with no new safety concerns identified during the study [4][20] Treatment Flexibility - INGREZZA is unique as the only VMAT2 inhibitor that allows patients to start at a therapeutic dose without the need for titration, providing flexibility in dosing based on individual response and tolerability [2][10]

Conference Call and Webcast Scheduled for Tuesday, October 28 , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on October 28, 2025. The schedule for the press release and conference call / webcast is as follows: The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webca ...

INGREZZA was generally well tolerated over the long term, and TEAEs observed in the study were consistent with its established safety profile and with known symptoms of Huntington's disease:Â Additional presentations at the 2025 MDS International Congress of Parkinson's Disease and Movement Disorders include: , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and susta ...

Core Insights - PGIM Jennison Health Sciences Fund's second-quarter 2025 investor letter highlights significant volatility in equities, with the S&P 1500 Health Care Index declining 6.9% while the S&P 500 returned 10.9% [1] - The fund's top holdings include Neurocrine Biosciences, Inc., which has shown a one-month return of 5.56% and a 52-week gain of 26.52% [2] Market Performance - The S&P 1500 Health Care Index underperformed the S&P 500 in June, gaining only 1.9% compared to the S&P 500's 5.1% [1] - Health care providers & services, life sciences tools & services, biotechnology, and pharmaceuticals underperformed the Index, while healthcare technology and medtech sectors gained [1] Company Focus: Neurocrine Biosciences, Inc. - Neurocrine Biosciences, Inc. reported stronger than expected first-quarter results and remains optimistic about its second-quarter performance, indicating a recovery from previous guidance issues [3] - As of September 24, 2025, Neurocrine's stock closed at $146.67 with a market capitalization of $14.547 billion [2] - The number of hedge funds holding Neurocrine decreased from 63 to 59 in the second quarter, suggesting a shift in investment interest [3]

Core Insights - The KINECT-PRO analysis is the first and only study to report both remission of tardive dyskinesia symptoms and improvements in patient-reported outcomes [1] - Post-hoc analysis from KINECT-PRO showed substantial symptomatic remission rates at Week 24, occurring earlier than in previous studies [1]

Core Insights - Neurocrine Biosciences, Inc. announced new data from the Phase 2 SAVITRI study demonstrating significant improvement in depression severity at Day 28 and Day 56 with the administration of 1 mg osavampator (NBI-1065845) [1] Group 1 - The Phase 2 SAVITRI study showed statistically significant improvement in depression severity [1] - The improvement was clinically meaningful at both Day 28 and Day 56 [1] - The treatment involved once-daily oral administration of 1 mg osavampator [1]